Crizotinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), CONITEC (Brazil) and G-BA (Germany), among others, recommended or restricted crizotinib, while AOTMIT (Poland) did not recommend it.
The file has been open for more than a decade: 12.9 years separate the first record, 21 Mar 2013 at AWMSG (Wales), from the most recent, 18 Feb 2026 at HAS (France).
TLV (Sweden) changed its position: restricted on 5 Mar 2014, recommended by 20 Jun 2016.
Every one of the eight highest-volume agencies in this archive has a record for crizotinib.
Not every gap is a refusal: for crizotinib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 8 of 35 records date from 2023 or later.
7 distinct indication wordings are recorded for crizotinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 35 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess crizotinib, on 21 Mar 2013; CIPM (Spain) did not open a file until 20 Nov 2024 — an unusually long tail of 11.7 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 12 years in total.
10 of the 12 agencies here assessed crizotinib more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
crizotinib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for crizotinib reads 21 recommended, 4 restricted, 3 deferred to NICE and 2 not recommended, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 21 Oct 2025 | Tratamento, em primeira linha, de pacientes adultos com câncer de pulmão não pequenas células avançado ou metastático AL… | excluded from SUS | source |
| NICE (England) | 4 Dec 2024 | NICE TA1021 | recommended (optimised) | source |
| CIPM (Spain) | 20 Nov 2024 | Indicaciones terapéuticas autorizadas: XALKORI en monoterapia está indicado para: El tratamiento de primera línea de adu… | financed by the SNS · art. 92 a, c | source |
| PHARMAC (New Zealand) | 21 Nov 2023 | Non-small cell lung cancer, locally advanced or metastatic, ROS1 gene translocation | PTAC advice: No Formal Recommendation · decision reached | source |
| SMC (Scotland) | 11 Sep 2023 | As monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with: relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplasti… | not recommended | source |
30 further decisions for crizotinib, across 11 agencies, are not shown here. They include the most recent record on file, 18 Feb 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 20 further source documents.
Related molecules
- sotorasib — divergent outcome (recommended vs not recommended) on a shared indication
- tarlatamab — divergent outcome (recommended vs not recommended) on a shared indication
- mobocertinib — divergent outcome (recommended vs withdrawn) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
Coverage: 35 decisions for crizotinib from 12 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.